CONTACT US
Home > Inhibitors/Agonists> > NSC-176377
20841-26-3-NSC-176377 NSC-176377

NSC-176377

For research use only. Not for therapeutic Use.

  • CAT Number: I033573
  • CAS Number: 20841-26-3
  • Molecular Formula: C15H17N3S
  • Molecular Weight: 271.38
  • Purity: 98%
Inquiry Now
Related Small Molecules: TLR7 agonist 4     Tetraheptylammonium iodide     Fludarabine triphosphate    

NSC-176377（Cat No.:I033573）is a small molecule compound primarily studied for its potential antitumor activity. It has shown promise in preclinical research as a selective inhibitor of certain kinases involved in cancer cell proliferation and survival. By targeting specific signaling pathways, NSC-176377 may help reduce tumor growth and enhance the effectiveness of other cancer therapies. Its mechanism of action is still under investigation, but it is believed to interfere with key molecular processes that support cancer cell viability. Further studies are required to assess its pharmacokinetics, safety, and potential as a therapeutic agent in oncology.


Catalog Number I033573
CAS Number 20841-26-3
Synonyms

NSC-176377; NSC176377; NSC 176377.

Molecular Formula C15H17N3S
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 1-(3-methylphenyl)-3-(2-pyridin-2-ylethyl)thiourea
InChI InChI=1S/C15H17N3S/c1-12-5-4-7-14(11-12)18-15(19)17-10-8-13-6-2-3-9-16-13/h2-7,9,11H,8,10H2,1H3,(H2,17,18,19)
InChIKey BYYMNCLQXIVWNA-UHFFFAOYSA-N
SMILES CC1=CC(=CC=C1)NC(=S)NCCC2=CC=CC=N2
Reference

1: Bangirana P, Ruel TD, Boivin MJ, Pillai SK, Giron LB, Sikorskii A, Banik A, Achan J. Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy. J Int AIDS Soc. 2017 Oct;20(2). doi: 10.1002/jia2.25015. PubMed PMID: 29052340.
2: Kundro MA, Viloria GA, Toibaro JJ, Losso MH. Antiretroviral therapy and arterial elasticity in HIV-infected patients. Medicina (B Aires). 2017;77(5):365-369. PubMed PMID: 29044011.
3: Tres F, Hall SD, Mohutsky MA, Taylor LS. Monitoring the Phase Behavior of Supersaturated Solutions of Poorly Water-Soluble Drugs Using Fluorescence Techniques. J Pharm Sci. 2017 Oct 11. pii: S0022-3549(17)30691-3. doi: 10.1016/j.xphs.2017.10.002. [Epub ahead of print] PubMed PMID: 29031978.
4: Jordan MR, Penazzato M, Cournil A, Vubil A, Jani I, Hunt G, Carmona S, Maphalala G, Mthethwa N, Watera C, Kaleebu P, Chakanyuka Musanhu C, Mtapuri-Zinyowera S, Dzangare J, Peeters M, Yang C, Parkin N, Bertagnolio S. HIV drug resistance in African infants and young children newly diagnosed with HIV: a multicounty analysis. Clin Infect Dis. 2017 Aug 8. doi: 10.1093/cid/cix698. [Epub ahead of print] PubMed PMID: 29020335.
5: Jantarabenjakul W, Anugulruengkitt S, Kasipong N, Thammajaruk N, Sophonphan J, Bunupuradah T, Cressey TR, Colbers A, Burger DM, Phongsamart W, Puthanakit T, Pancharoen C; HIVNAT 220 study. Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically-suppressed HIV-1-infected adolescents. Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3198. [Epub ahead of print] PubMed PMID: 28994660.
6: Memarnejadian A, Gouklani H, Mohammadi S, Moosazadeh M, Choi J. Prevalence of HIV-1 pre-treatment drug resistance in a southern province of Iran, 2016-2017. Arch Virol. 2017 Oct 5. doi: 10.1007/s00705-017-3572-1. [Epub ahead of print] PubMed PMID: 28983848.
7: Gong T, Zhang W, Parniak MA, Graebing PW, Moncla B, Gupta P, Empey KM, Rohan LC. Preformulation and Vaginal Film Formulation Development of Microbicide Drug Candidate CSIC for HIV prevention. J Pharm Innov. 2017 Jun;12(2):142-154. doi: 10.1007/s12247-017-9274-0. Epub 2017 Mar 3. PubMed PMID: 28983328; PubMed Central PMCID: PMC5624728.
8: Inzaule SC, Osi SJ, Akinbiyi G, Emeka A, Khamofu H, Mpazanje R, Ilesanmi O, Ndembi N, Odafe S, Sigaloff KCE, Rinke de Wit TF, Akanmu S. High prevalence of HIV drug resistance among newly diagnosed infants aged <18 months: results from a nationwide surveillance in Nigeria. J Acquir Immune Defic Syndr. 2017 Sep 25. doi: 10.1097/QAI.0000000000001553. [Epub ahead of print] PubMed PMID: 28961680.
9: Pessôa R, Sanabani SS. High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors. PLoS One. 2017 Sep 27;12(9):e0185559. doi: 10.1371/journal.pone.0185559. eCollection 2017. PubMed PMID: 28953964; PubMed Central PMCID: PMC5617215.
10: Al-Salama ZT. Elsulfavirine: First Global Approval. Drugs. 2017 Sep 23. doi: 10.1007/s40265-017-0820-3. [Epub ahead of print] PubMed PMID: 28940154.
11: Santoro MM, Di Carlo D, Armenia D, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Antoni AMD, Lagi F, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V, Sterrantino G. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2017 Sep 22. doi: 10.3851/IMP3197. [Epub ahead of print] PubMed PMID: 28935850.
12: Contreras-Galindo RA, Dube D, Fujinaga K, Kaplan MH, Markovitz DM. Susceptibility of Human Endogenous Retrovirus Type-K to Reverse Transcriptase Inhibitors. J Virol. 2017 Sep 20. pii: JVI.01309-17. doi: 10.1128/JVI.01309-17. [Epub ahead of print] PubMed PMID: 28931682.
13: Sharaf NG, Xi Z, Ishima R, Gronenborn AM. The HIV-1 p66 homodimeric RT exhibits different conformations in the binding-competent and -incompetent NNRTI site. Proteins. 2017 Sep 14. doi: 10.1002/prot.25383. [Epub ahead of print] PubMed PMID: 28905420.
14: Kan W, Teng T, Liang S, Ma Y, Tang H, Zuohela T, Sun G, He C, Wall KM, Marconi VC, Liao L, Leng X, Liu P, Ruan Y, Xing H, Shao Y. Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study. BMJ Open. 2017 Sep 7;7(9):e016012. doi: 10.1136/bmjopen-2017-016012. PubMed PMID: 28882911; PubMed Central PMCID: PMC5595192.
15: Jones E, Mazirka P, McNurlan MA, Darras F, Gelato MC, Caso G. Highly active antiretroviral therapy dysregulates proliferation and differentiation of human pre-adipocytes. World J Virol. 2017 Aug 12;6(3):53-58. doi: 10.5501/wjv.v6.i3.53. PubMed PMID: 28868243; PubMed Central PMCID: PMC5561499.
16: Corona A, Onnis V, Deplano A, Bianco G, Demurtas M, Distinto S, Cheng YC, Alcaro S, Esposito F, Tramontano E. Design, synthesis and antiviral evaluation of novel heteroarylcarbothioamide derivatives as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and RDDP functions. Pathog Dis. 2017 Aug 31;75(6). doi: 10.1093/femspd/ftx078. PubMed PMID: 28859311.
17: Bastida C, Grau A, Márquez M, Tuset M, De Lazzari E, Martínez E, Gatell JM. Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population. Farm Hosp. 2017 Sep 1;41(5):618-624. doi: 10.7399/fh.10778. PubMed PMID: 28847251.
18: Ayele TA, Worku A, Kebede Y, Alemu K, Kasim A, Shkedy Z. Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies. Syst Rev. 2017 Aug 25;6(1):173. doi: 10.1186/s13643-017-0567-7. PubMed PMID: 28841912; PubMed Central PMCID: PMC5574138.
19: Jin J, Grimmig B, Izzo J, Brown LAM, Hudson C, Smith AJ, Tan J, Bickford PC, Giunta B. HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo. Cell Transplant. 2016 Nov;25(11):1967-1977. doi: 10.3727/096368916X691457. PubMed PMID: 28836850.
20: Paemanee A, Sornjai W, Kittisenachai S, Sirinonthanawech N, Roytrakul S, Wongtrakul J, Smith DR. Nevirapine induced mitochondrial dysfunction in HepG2 cells. Sci Rep. 2017 Aug 23;7(1):9194. doi: 10.1038/s41598-017-09321-y. PubMed PMID: 28835669; PubMed Central PMCID: PMC5569014.

Request a Quote